Table 2.
Patient driver oncogene status
| Major driver oncogenes | n (%) | PD-L1 expression | P | |||
|---|---|---|---|---|---|---|
|
| ||||||
| ≥1% | P | ≥50% | P | |||
| EGFR status | 457 | 137 (30.0) | 37(8.1) | |||
| Adenocarcinoma | 421 (92.1) | 0.006* | <0.001* | 0.005* | ||
| Wild type | 171 (40.6) | 60 (35.1) | 22 (12.9) | |||
| L858R | 117 (27.8) | 22 (18.8) | 2 (1.7) | |||
| Exon 19 deletion | 114 (27.1) | 29 (25.4) | 5 (4.4) | |||
| Others† | 19 (4.5) | 6 (31.6) | 1 (5.3) | |||
| Squamous cell carcinoma | 19 (4.2) | |||||
| Wild type | 19 (9.5) | 13 (68.4) | 5 (26.3) | |||
| Adenosquamous carcinoma | 8 (1.8) | |||||
| Wild type | 3 (1.5) | 1 (33.3) | 0 | |||
| L858R | 2 (40.0) | 1 (50.0) | 0 | |||
| Exon 19 deletion | 2 (40.0) | 1 (50.0) | 0 | |||
| T790M+L858R | 1 (20.0) | 0 | 0 | |||
| Lymphoepithelioma-like carcinoma | 2 (0.4) | |||||
| Wild type | 1 (50.0) | 1 (50.0) | 1 (50.0) | |||
| Exon 19 deletion | 1 (50.0) | 0 | 0 | |||
| Other tumors | 7 (1.5) | |||||
| Wild type | 7 (100) | 3 (42.9) | 1 (14.3) | |||
| ALK status | 1034 | 346 (33.5) | 115 (11.1) | |||
| Adenocarcinoma | 825 (77.8) | 0.038* | 0.505 | 0.222 | ||
| Wild type | 788 (95.5) | 199 (25.3) | 59 (7.5) | |||
| Rearrangement | 37 (4.5) | 15 (40.5) | 3( 8.1) | |||
| Squamous cell carcinoma | 172 (16.6) | |||||
| Wild type | 170 (98.8) | 113 (66.5) | 41 (24.1) | |||
| Rearrangement | 2 (1.2) | 1 (50.0) | 0 | |||
| Adenosquamous carcinoma | 13 (1.3) | |||||
| Wild type | 11 (84.6) | 3 (27.3) | 1 (50.0) | |||
| Rearrangement | 2 (15.4) | 2 (100) | 0 | |||
| Neuroendocrine tumor | 11 (1.1) | 0 | ||||
| Wild type | 10 (90.9) | 2 (20.0) | 1 (10.0) | |||
| Rearrangement | 1 (9.1) | 0 | 0 | |||
| Other tumors | 13 (1.3) | |||||
| Wild type | 13 (100) | 11 (84.6) | 10 (76.9) | |||
*
Significant P values.
†
Insertion in exon 20 (n=6), G719X (n=5), L861Q (n=4), L858R+T790M (n=1), 19Del+T790M (n=2), G719X+T790M (n=1).